Literature DB >> 8392272

A second thought on second look laparotomy.

A Bar-Am1, F Kovner, J B Lessing, M Inbar, S Chaitchik, F Azem, S H Brenner, M R Peyser.   

Abstract

Between 1982 and 1987, 43 patients with epithelial ovarian carcinoma, identified as International Federation of Gynaecology and Obstetrics Stages I-IV, underwent second-look laparotomy as a part of their treatment protocol. Twenty-nine patients (67%) had no evidence of residual disease, five (11.6%) had residual disease < or = 1 cm, and nine patients (20%) had residual disease > or = 1 cm at re-exploration. Persistent disease at the second operation was positively correlated with the initial clinical stage, and negatively correlated with the extent of the original cytoreductive surgery. Fifteen of 29 patients with negative findings (52%) developed recurrent disease within two years. All recurrences were limited to the abdominal cavity only. Three and five years survival, for the patients with negative findings, was 62% and 48% respectively. No documented benefit to the patients could be demonstrated by adopting second-look laparotomy as a routine procedure in the management of patients with epithelial ovarian carcinoma. In view of our data, as well as that of others, such operations cannot be considered a valuable routine procedure. At this point, second-look laparotomy may have a role in evaluating the efficacy of a post-surgical new chemotherapy treatment regimen.

Entities:  

Mesh:

Year:  1993        PMID: 8392272     DOI: 10.3109/00016349309021119

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

Review 1.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

2.  [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.

Authors:  Sungeun Kim; June-Key Chung; Soon-Beom Kang; Moon-Hong Kim; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.